Arcus Biosciences, Inc.RCUS決算レポート
NYSE · biotechnology industry
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
主要株主
| 株主 | 保有比率 | 株数 | 変動 | 基準日 |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 35.00% | 31.5M | 変動なし | 2024-01-31 |
| BlackRock, Inc. | 10.60% | 9.7M | 変動なし | 2024-11-08 |
| The Vanguard Group | 6.25% | 4.7M | — | 2024-02-13 |
| FMR LLC | 4.89% | 4.5M | ▼ -1.43pp | 2024-11-12 |
| Terry Rosen, Ph.D. | 4.10% | 3.8M | — | 2024-12-17 |
| STATE STREET CORPORATION | 3.30% | 3.0M | ▼ -2.36pp | 2024-10-17 |
インサイダー取引
Net 90d: +$0 · buys $0 / sells $0期間:
種別:
役職:
条件に一致する取引はありません。